Hitachi Chemical will enter into an agreement to acquire all shares of Apceth Biopharma, a contract manufacturing organization in the field of cell and gene therapy. With the acquisition Hitachi Chemical is to expand its business presence footprint in Europe ― the world’s second-largest market for regenerative medicine after the United States.
Munich/Germany — Founded 2007, Apceth is a pioneer in cell and gene therapy and has developed into a leading European contract development and manufacturing organization (CDMO) for Advanced Therapy Medicinal Products (ATMPs). The company has state-of-the-art facilities located in Munich, Germany, which are fully compliant with all current EU ATMP regulations, BSL2 and ICH guidelines.
According Christine Guenther, MD, CEO of Apceth Biopharma, the combined strengths within Hitachi Chemical would allow the company to manufacture complex cell and gene therapies for clients in North America, Asia, and Europe. This acquisition is expected to close in April 2019.